✨ Free AI Report
Actuate Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Actuate Therapeutics, Inc.
Company Research

Actuate Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Actuate Therapeutics is a clinical-stage biopharmaceutical company developing therapies for difficult-to-treat cancers through GSK-3 inhibition, with its lead product candidate elraglusib in Phase 2 trial for metastat...

Analyst-debate audio for Actuate Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Actuate Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
4/ 10Mixed

Cyborg Score thesis

Early-stage GSK-3 inhibitor play in hard-to-treat cancers; significant clinical and execution risk outweighs mechanism novelty;...

Read the full analyst-debate transcript →
Industry Oncology Drugs
6 named competitors
2 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 21, 2026
AI-Verified Research
30+ Page Report

Get the Latest Actuate Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Actuate Therapeutics, Inc. Overview

Pro stress-test →

Actuate Therapeutics is a clinical-stage biopharmaceutical company developing therapies for difficult-to-treat cancers through GSK-3 inhibition, with its lead product candidate elraglusib in Phase 2 trial for metastatic pancreatic ductal adenocarcinoma. The company operates as a semi-virtual biopharmaceutical organization with a lean footprint.

Strategic Profile

Pro stress-test →

Actuate is executing multiple clinical trials including Phase 2 for myelofibrosis, Phase 1/2 for pediatric neuroblastoma, and Phase 2 for salivary gland carcinomas. The company's focus on GSK-3β inhibition targets multiple oncogenic pathways in drug-resistant cancers, positioning it in the competitive oncology therapeutics market where clinical-stage biotech programs targeting unmet needs in solid and hematologic malignancies command premium valuations pending trial outcomes.

Competitive Landscape

Pro stress-test →

Actuate competes in the clinical-stage oncology therapeutics space against established immunotherapy platforms (checkpoint inhibitors, CAR-T cell therapies) and conventional chemotherapy regimens. Direct competitors include other GSK-3 pathway programs and multi-mechanism cancer platforms from better-capitalized clinical-stage and commercial biotech firms. Key differentiation hinges on elraglusib's ability to overcome chemotherapy resistance and enhance immune activation in patient populations where existing therapies have failed.

Industry Context

Actuate Therapeutics, Inc. operates in Oncology Drugs.

Key facts

Founded: 2015 · Headquarters: Fort Worth, Texas, US · Employees: 12 · Market cap: $33.5M (as of July 2026)

What the analysts stress-tested

The top findings that survived the multi-agent debate for Actuate Therapeutics, Inc..

  • Elraglusib targets GSK-3β to drive tumor cell death and enhance anti-tumor immunity. Clinical stage with no marketed products or revenue; value hinge on Phase 2 pancreatic, pediatric, and salivary gland trial readouts in 2026–2027.
  • Company operates semi-virtual model with 12 employees and contracts external development teams across US, Europe, and Canada. Low fixed-cost structure mitigates burn rate but limits in-house scientific depth and reduces competitive moat versus well-funded rivals.
+1 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • March 2026Q4 2025 annual report published, disclosing clinical trial progress and financial position
  • April 2026Proxy statement filed ahead of shareholder vote; analyst rerating by H.C. Wainwright lowered price target to $15 from $20 while maintaining Buy rating
Get alerted when Actuate Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Adaptimmune TherapeuticsT-cell receptor engineered cell therapies for cancer→Inovio PharmaceuticalsDNA-based immunotherapies for cancer and infectious disease→Carisma TherapeuticsOff-the-shelf cell immunotherapy for solid tumors→Jounce TherapeuticsClinical-stage immunotherapy company developing checkpoint modulator therapies for difficult-to-treat cancers→Surface OncologyClinical-stage immunotherapy company developing cancer therapies targeting immune checkpoints and cell surface receptors→Arcus BiosciencesClinical-stage biopharmaceutical company developing immuno-oncology therapies for difficult-to-treat cancers→

Compare Actuate Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Actuate Therapeutics, Inc. operates in Oncology Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Oncology Drugs research →
NEW · MCP server

Ask your AI assistant about Actuate Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Actuate Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Actuate Therapeutics, Inc. do this quarter?”
“Is Actuate Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Actuate Therapeutics, Inc. do?+
Actuate Therapeutics is a clinical-stage biopharmaceutical company developing therapies for difficult-to-treat cancers through GSK-3 inhibition, with its lead product candidate elraglusib in Phase 2 trial for metastat...
What is Actuate Therapeutics, Inc.'s Cyborg Score?+
Actuate Therapeutics, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Actuate Therapeutics, Inc.'s main competitors?+
Named competitors include Adaptimmune Therapeutics, Inovio Pharmaceuticals, Carisma Therapeutics, Jounce Therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full Actuate Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Actuate Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Actuate Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.